Nutra Pharma Corp.

NPHC

US67060U2087

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:18:22 2026-06-22 pm EDT			5-day change	1st Jan Change
0.000200 ^USD	+100.00%		0.00%	+100.00%

May. 29	Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 20	Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 04/06/2026 at 05:10 pm EDT

S&P Capital IQ

NUTRA PHARMA CORP.

+100.00%

INR / USD

-0.10%

Nutra Pharma Corp. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported sales was USD 0.098704 million compared to USD 0.10947 million a year ago. Net loss was USD 0.52352 million compared to USD 0.260683 million a year ago.
For the nine months, sales was USD 0.331241 million compared to USD 0.27062 million a year ago. Net loss was USD 1.56 million compared to USD 1.05 million a year ago.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	NUTRA PHARMA CORP.	0.000200USD	+100.00%	0.00%	1.43M
	INDIAN RUPEE / US DOLLAR	0.0106USD	-0.10%	0.00%	-

Latest news about Nutra Pharma Corp.

May. 29	Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 20	Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 19	Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	CI
Apr. 06	Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Mar. 25	Nutra Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Mar. 11	Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
Feb. 17	Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
Feb. 16	Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	CI
Jan. 02	Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
Dec. 23	Nutra Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
Dec. 17	Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Nov. 24	Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Nov. 23	Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	CI
25-10-28	Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
25-10-23	Nutra Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Chart Nutra Pharma Corp.

Duration

Period

NPHC: Dynamic Chart

Company Profile

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. RPI-MN is used to treat neurological diseases and autoimmune diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrigâ€™s disease), Rheumatoid Arthritis (RA) and Myasthenia Gravis. The RPI-78M is used to treat viral diseases, including HIV/AIDS and Herpes. The Company offers Nyloxin/Nyloxin Extra Strength as its over-the-counter (OTC) pain reliever. It is focused upon marketing homeopathic drugs for the treatment of pain: Nyloxin, Nyloxin Extra Strength Pet Pain, Equine Pain, and Luxury Feet.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data